Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Epitelijski rak jajčnikov, rak jajcevodov, primarni peritonealni serozni karcinom (PPSC) : priporočila za sistemsko zdravljenje
Authors:Škof, Erik (Author)
Cerar, Olga (Author)
Tipology:1.01 - Original Scientific Article
Organisation:Logo OI - Institute of Oncology
Keywords:rak (medicina), jajčniki, kemoterapija, zdravljenje, smernice
Year of publishing:2015
COBISS_ID:2139259 Link is opened in a new window
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
Files:.pdf PDF - Presentation file, download (1,66 MB)
Onkološki inštitut
Rights:by Authors
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:03.01.2018

Secondary language

Title:Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal serous cancer (PPSC) : systemic treatment recommendations
Abstract:Epithelial ovarian cancer is known to be one of the most sensitive to systemic treatment with chemotherapy. Objective response to treatment was achieved in more than 80% of patients. Therefore, chemotherapy treatment is a standard part of primary treatment after completed surgery (adjuvant treatment), If surgical treatment is not possible, patients begin treatment with preoperative (neoadjuvant) chemotherapy, which is followed by surgery. In primary systemic treatment, we have been using chemotherapy in combination with taxanes and platinum-based preparations. In systemic treatment of fallopian tube cancer, we also use – besides chemotherapy – bevacizumab, an inhibitor of the vascular endothelial growth factor (VEGF). Systemic treatment presents the principal treatment also in disease recurrence. The type of systemic treatment in disease recurrence depends on the time elapsed since the end of primary treatment until recurrence. In the last couple of years, we have been again witnessing the introduction of new medicines for treatment of patients with fallopian tube cancer. For this reason, the Institute of Oncology Ljubljana this year updated its guidelines for systemic treatment of epithelial ovarian cancer. In this paper, we present the current recommendations for systemic treatment of epithelial ovarian cancer in Slovenia. Epithelial ovarian cancer, fallopian tube cancer and primary peritoneal serous cancer (PPSC) have the same clinical course and the same systemic treatment, therefore they are all managed in the same manner.